In view of  increasing demand for innovative inhalation system, the research-driven pharma company - Boehringer Ingelheim is investing approximately Euro 85 million in its Dortmund facility to double the Respimat soft inhalers production to 44 million annually by 2015.

A successful treatment of respiratory diseases depends on how much of the active substance enters into the patient's lung. Boehringer Ingelheim's Respimat soft inhaler and its long-lasting aerosol cloud effectively transport the active substance into the patient's lung.

“We expect that the Respimat business will continue its strong growth. For this reason, Boehringer Ingelheim is now laying the symbolic foundation stone to expand production capacity for the Respimat soft inhaler at the Dortmund facility. In future, we will continue to meet the increasing demand, while at the same time fulfilling our claim to provide patients with innovative medications", stated Professor Wolfram Carius, member of Boehringer Ingelheim’s Board of Managing Directors in charge of Biopharmaceuticals and Operations. “Doubling our Respimat production capacity will allow us to produce up to 44 million inhalers annually in the future. The success story of Respimat continues.” The Respimat Soft Inhaler is produced in Dortmund by subsidiary Boehringer Ingelheim microParts GmbH. Part of the Boehringer Ingelheim group since 2004, it man

“North Rhine-Westphalia is Germany’s industrial hub – and by investing millions here in Dortmund, Boehringer Ingelheim is underscoring the importance of our state to industry“, emphasised Garrelt Duin, Minister of Economic Affairs, Energy, Industry, SMEs and Trade for the State of North Rhine-Westphalia at the start of production capacity expansion in Dortmund. “To develop such high technology, a long-term effort is required before the whole thing really pays off“, said Duin. “North Rhine-Westphalia and the City of Dortmund are very fortunate that as a family-owned company, Boehringer Ingelheim has the necessary stamina.”

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.